Therefore, XPO1 could be an excellent therapeutic target in breast cancer as XPO1 is already targeted in other therapy-resistant cancers with the highly specific small molecule inhibitor SEL, which is an orally active and well-tolerated drug [14,15]. The gene discussed is XPO1; the disease is cancer.